Depletion of conventional CD4<sup>+</sup> T cells is required for robust priming and dissemination of tumor antigen-specific CD8<sup>+</sup> T cells in the setting of anti-CD4 therapy
These findings underscore the underappreciated benefit of depleting CD4<sup>+</sup> Tconv cells to promote systemic primary and memory CD8<sup>+</sup> T cell responses against cancer.
Authors
- Wilson L. Davis
- J. Louise Lines (ORCID: https://orcid.org/0000-0002-3766-8376)
- Aaron R Hawkes
- Nathaniel Spicer (ORCID: https://orcid.org/0000-0002-9106-1049)
- Joseph D. Phillips (ORCID: https://orcid.org/0000-0001-9309-7726)
- Tiffany Chen (ORCID: https://orcid.org/0000-0003-2546-2941)
- Keisuke Shirai (ORCID: https://orcid.org/0000-0002-1403-8128)
- Christo Philip C. Dragnev (ORCID: https://orcid.org/0009-0003-7877-8058)
- Tyler G. Searles (ORCID: https://orcid.org/0000-0003-3146-4812)
- Pamela C. Rosato (ORCID: https://orcid.org/0000-0001-7909-3868)
- Mary Jo Turk (ORCID: https://orcid.org/0000-0002-9612-8329)
- Yina H. Huang (ORCID: https://orcid.org/0000-0002-0125-9351)
- Asmaa Mohamed (ORCID: https://orcid.org/0000-0002-8717-2416)
- Delaney E Ramirez
Institutions
- Dartmouth College (US)
- Dartmouth Psychiatric Research Center (US)
- Dartmouth Health (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-010170
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Dartmouth College
- Dartmouth Cancer Center
- National Institutes of Health